Trials / Completed

CompletedNCT00954681

Study of Quetiapine Treatment for Cannabis Dependence

Open-Label Pilot Study of Quetiapine Treatment for Cannabis Dependence

Status: Completed
Phase: Phase 2
Study type: Interventional
Enrollment: 15 (actual)

Sponsor: New York State Psychiatric Institute · Academic / Other
Sex: All
Age: 18 Years – 65 Years
Healthy volunteers: Not accepted

Summary

Marijuana is the most commonly used illicit drug in the United States. However, the treatment options for cannabis dependence are limited; notably, no effective pharmacotherapy has been developed. Conceptually, the ideal medication treatment for cannabis dependence would: 1. be safe when administered to patients actively using cannabis 2. reduce cannabis intake and promote abstinence 3. treat the symptoms of cannabis withdrawal 4. reduce craving and relapse risk 5. have a low abuse liability.

Detailed description

Conceptually, the pharmacodynamic and clinical actions of quetiapine suggest that it may be useful for cannabis dependence. By antagonizing dopamine, quetiapine may interfere with the reinforcing effects of cannabis, while serotonin type 2A, histamine type 1, and adrenergic receptor antagonism may reduce cannabis withdrawal symptoms, primarily by sedating and anxiolytic effects. The proposed research project is an open-label pilot study to evaluate the tolerability and ideal target dosing range for quetiapine treatment of cannabis dependence over an eight-week period. The purpose of this pilot study is to obtain preliminary data regarding the potential efficacy, tolerability and safety of quetiapine treatment of cannabis dependence before conducting a larger double-blind trial.

Conditions

Cannabis Dependence

Interventions

Type	Name	Description
DRUG	quetiapine	Quetiapine treatment from 25 mg daily to 300 mg twice daily

Timeline

Start date: 2009-08-01
Primary completion: 2010-08-01
Completion: 2010-08-01
First posted: 2009-08-07
Last updated: 2019-04-24
Results posted: 2017-09-06

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00954681. Inclusion in this directory is not an endorsement.